Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc., recently executed a transaction involving common stock, according to filings with the SEC. On May 15, 2026, Mr. Dickinson sold 3,000 shares of the company's common stock, totaling $396,810 in value.
The sale was conducted at a price point of $132.27 per share. Following this specific transaction, internal records indicate that Mr. Dickinson directly holds 173,191 shares of Gilead Sciences common stock. It is noteworthy that the disposal of these shares was executed under the framework of a Rule 10b5-1 trading plan, which had been formally adopted on August 29, 2024.
The current market price for GILD stands at $129.67, marking a decline from the sale price. Despite this recent movement, the stock has delivered a substantial return of 29.78% over the past year. Furthermore, an analysis provided by InvestingPro suggests that Gilead might be undervalued at its current valuation levels, assigning it a Fair Value estimate of $139.49.
From a structural financial perspective, the biotechnology firm maintains a market capitalization of $161.43 billion and offers investors a 2.53% dividend yield. InvestingPro subscribers also have access to additional insights concerning GILD, including details on the company's history of increasing dividends for 11 consecutive years.
Beyond insider activity, Gilead Sciences provided several significant operational updates in its recent first-quarter 2026 earnings report. The results exceeded what analysts had projected. Specifically, the non-GAAP diluted Earnings Per Share (EPS) reached $2.03, surpassing the forecasted figure of $1.90. Concurrently, the company's revenue was reported at $7 billion, which is higher than the anticipated projection of $6.91 billion.
In a positive development following these strong results, Gilead adjusted its 2026 revenue guidance, increasing the forecast by $400 million. The market also reacted to these developments through analyst coverage. Morgan Stanley revised its price target for Gilead Sciences, lowering it from $175 down to $168, while simultaneously maintaining an Overweight rating.
The company continues to pursue strategic financial activities and clinical research milestones. In a move reflecting its post-acquisition strategy, Gilead launched its first investment-grade bond offering in 18 months. This offering involves notes structured in up to four parts, with maturity periods spanning from two years to eight years. Additionally, the firm announced plans to present findings derived from 29 abstracts at the European Association for the Study of the Liver Congress.
Other financial institutions also provided commentary on GILD. RBC Capital reiterated a Sector Perform rating on Gilead Sciences, setting a price target of $122. Their analysis specifically mentioned the company's drug candidate for ulcerative colitis, emvistegrast, noting that Phase II data is anticipated in the near future.
Risks
- Fluctuations from Insider Trading Activity
- Market Sensitivity to Price Target Adjustments
- Dependence on Future Clinical Data Milestones
More from Insider Trading
Risks
- Fluctuations from Insider Trading Activity
- Market Sensitivity to Price Target Adjustments
- Dependence on Future Clinical Data Milestones